Abstract
Hormone replacement therapy (HRT) is traditionally contraindicated in breast cancer survivors. However, recent trends in early detection and treatment have produced larger numbers of cured women who are likely to die of non-cancer causes. They also face morbidity from menopausal symptoms and osteoporotic fractures. HRT significantly reduces the risk of cardiovascular disease and usually eliminates menopausal symptoms and osteoporosis. But HRT could degrade mammographic quality, promote development of new breast cancers or activate dormant tumor cells. Clinical trials of HRT in breast cancer survivors are beginning in order to address these important concerns.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
